INS and metabolic dysfunction-associated steatotic liver disease: Studies have shown that FGF1 reduces blood sugar by increasing insulin sensitivity, providing a new approach for the treatment of metabolic diseases like fatness, NAFLD and T2DM (Jonker et al., 2012; Suh et al., 2014).